Screener
Recursion Pharmaceuticals, Inc. RXRX Materials received not invoiced
Materials received not invoiced at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rxrx:MaterialsReceivedNotInvoiced.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| (in thousands) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued development expenses | 4,298 | 2,693 |
| Accrued early discovery expenses | 4,621 | 4,581 |
| Accrued professional fees | 1,167 | 1,232 |
| Materials received not invoiced | 171 | 703 |
| Accrued taxes, other than income taxes | 3,557 | 3,912 |
| Unearned grants | 1,909 | — |
| Accrued license fees | 3,000 | 3,000 |
| Accrued other expenses | 13,458 | 14,060 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s materials received not invoiced?
- Recursion Pharmaceuticals, Inc. (RXRX) reported materials received not invoiced of $171K in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s materials received not invoiced changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s materials received not invoiced decreased by 88.9% year-over-year, from $1.54M to $171K.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s materials received not invoiced?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s materials received not invoiced has grown at a -29.8% compound annual growth rate (CAGR), from $2.03M to $703K.
- What does materials received not invoiced mean?
- Materials received not invoiced as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s materials received not invoiced.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude